

In the Specification

On page 1, between the title and line 4, add the following new paragraph:

-- Cross Reference to Related Applications.

✓
A
This application claims priority from United States provisional applications Serial Nos. 60/107792, filed November 10, 1998 and 60/143962, filed July 15, 1999, and PCT International application no. PCT/EP99/07417, filed September 24, 1999, the contents of each of which are hereby incorporated by reference.--

In the Claims:

✓
In Claim 3, line 1, replace "claim 1 or 2" with --claim 1--.

✓
In Claim 4, line 1, replace "any one of claims 1 to 3" with --claim 1--.

✓
In Claim 5, line 1, replace "any one of claims 1 to 4" with --claim 1--.

✓
In Claim 6, line 1, replace "any one of claims 1 to 5" with --claim 1--.

✓
In Claim 11, lines 2-3, replace "any one of claims 1 to 6" with --claim 1--.

✓
In Claim 13, line 1, replace "characterized by" with

--comprising--.


In Claim 14, line 1, replace "claim 1 or 8" with --claim 1--.

In Claim 16, line 1, replace "claim 1 or 8" with --claim 1--.

In Claim 17, line 2, replace "claim 1 or 8" with --claim 1--.

Cancel Claims 7 and 15 without prejudice and amend Claims 8, 9, 10 and 12 as follows:

8. (Amended) A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of [The use of] a compound of formula



a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

-a¹=a²-a³=a⁴- represents a bivalent radical of formula


- CH=CH-CH=CH- (a-1);
- N=CH-CH=CH- (a-2);
- N=CH-N=CH- (a-3);
- N=CH-CH=N- (a-4);
- N=N-CH=CH- (a-5);

n is 0, 1, 2, 3 or 4; and in case -a¹=a²-a³=a⁴- is (a-1), then n may also be 5;

R¹ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy;

C1-6alkyloxyC1-6alkylcarbonyl substituted with
C1-6alkyloxycarbonyl;

C1
cont
each R² independently is hydroxy, halo, C1-6alkyl optionally
substituted with cyano or -C(=O)R⁶, C3-7cycloalkyl, C2-6alkenyl
optionally substituted with one or more halogen atoms or
cyano, C2-6alkynyl optionally substituted with one or more
halogen atoms or cyano, C1-6alkyloxy, C1-6alkyloxycarbonyl,
carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino,
polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -
S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂,
-NHC(=O)R⁶, -C(=NH)R⁶ or a radical of formula



R²
wherein
or CR⁶;

each A independently is N, CH

B is NH, O, S or NR⁶;

p is 1 or 2; and

R⁶ is methyl, amino, mono- or

dimethylamino or polyhalomethyl;

L is C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-7cycloalkyl,
whereby each of said aliphatic group may be substituted with
one or two substituents independently selected from

- * C3-7cycloalkyl,
- * indolyl or isoindolyl, each optionally substituted with
one, two, three or four substituents each independently
selected from halo, C1-6alkyl, hydroxy, C1-6alkyloxy,
cyano, aminocarbonyl, nitro, amino, polyhalomethyl,
polyhalomethyloxy and C1-6alkylcarbonyl,
- * phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl,
wherein each of said aromatic rings may optionally be
substituted with one, two, three, four or five
substituents each independently selected from the
substituents defined in R²; or

L is -X-R³ wherein

R³ is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or
pyridazinyl, wherein each of said aromatic rings may

optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R^2 ; and

X is $-NR^1-$, $-NH-NH-$, $-N=N-$, $-O-$, $-C(=O)-$, $-CHOH-$, $-S-$, $-S(=O)-$ or $-S(=O)_2-$;

Q represents hydrogen, C_{1-6} alkyl, halo, polyhalo C_{1-6} alkyl or $-NR^4R^5$; and

R^4 and R^5 are each independently selected from hydrogen, hydroxy, C_{1-12} alkyl, C_{1-12} alkyloxy, C_{1-12} alkylcarbonyl, C_{1-12} alkyloxycarbonyl, aryl, amino, mono- or di(C_{1-12} alkyl)amino, mono- or di(C_{1-12} alkyl)aminocarbonyl wherein each of the aforementioned C_{1-12} alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C_{1-6} alkyloxy, hydroxy C_{1-6} alkyloxy, carboxyl, C_{1-6} alkyloxycarbonyl, cyano, amino, imino, mono- or di(C_{1-6} alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, $-S(=O)_pR^6$, $-NH-S(=O)_pR^6$, $-C(=O)R^6$, $-NHC(=O)H$, $-C(=O)NHNH_2$, $-NHC(=O)R^6$, $-C(=NH)R^6$, aryl and Het; or R^4 and R^5 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C_{1-12} alkyl)amino C_{1-4} alkylidene;

Y represents hydroxy, halo, C_{3-7} cycloalkyl, C_{2-6} alkenyl optionally substituted with one or more halogen atoms, C_{2-6} alkynyl optionally substituted with one or more halogen atoms, C_{1-6} alkyl substituted with cyano or $-C(=O)R^6$, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C_{1-6} alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, $-S(=O)_pR^6$, $-NH-S(=O)_pR^6$, $-C(=O)R^6$, $-NHC(=O)H$, $-C(=O)NHNH_2$, $-NHC(=O)R^6$, $-C(=NH)R^6$ or aryl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano, nitro, polyhalo C_{1-6} alkyl and polyhalo C_{1-6} alkyloxy;

C1
cont

Let is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.]

A2

for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.]

9. (Amended) A method of treating [The use of a compound as claimed in any one of claims 1 to 6 for the manufacture of a medicine for the treatment of] subjects suffering from Human Immunodeficiency Virus infection comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

Sub
D1

10. (Amended) The [use of a compound as claimed in any one of claims 1 to 6] method of Claim 9, wherein R¹ is hydrogen, aryl, formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl [for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection].

A2

12. (Amended) A process for preparing a pharmaceutical composition [as claimed in claim 11 characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6 is intimately mixed] comprising mixing the compound of claim 1 with a pharmaceutically acceptable carrier.